COVID-19: an Introductory course

Examine SARS-CoV-2 structure, its spike, nucleocapsid, envelope, and membrane proteins, and how spike S1/S2 enables cell entry and immunogenic responses, with a 29,000-letter RNA genome.

Learn how SARS-CoV-2 uses the ACE2 receptor on lung, nose, intestine, and kidney cells, via spike protein, to enter, replicate, assemble virions, and trigger apoptosis, lysis, or cell fusion.

Explore how viral mutation and recombination drive evolution under natural selection, detailing synonymous, nonsense, and missense changes, antigenic drift, immune evasion, and the emergence of variants of concern and interest.

Understand COVID-19 transmission via droplets and aerosols, direct and indirect contact, and fecal-oral routes; the disease genesis from viral replication to the cytokine storm, and five phases including asymptomatic.

Explore how to search the NCBI database for the SARS-CoV-2 reference genome, view its nucleotide sequence and translated proteins, and visualize open reading frames such as spike and membrane proteins.

Explore the three-dimensional spike glycoprotein and AC two receptors in the PDB database, viewing amino acid sequences and structural data with methods like electron microscopy and X-ray crystallography.

Explore the drug development pipeline from preclinical in vitro and in vivo studies to phase I and II clinical trials. Focus on safety, dosage, and early efficacy signals.

Explore phase three and four clinical trials, highlighting randomized, double-blind, placebo-controlled designs, large patient populations, safety and efficacy assessments, and postmarket monitoring by regulatory authorities.

Drug repurposing accelerates covid-19 research by testing already approved drugs for new diseases, leveraging known safety to assess efficacy in targeted clinical trials.

Explore the proposition of chloroquine and hydroxychloroquine for COVID-19, tracing origins from quinine used against malaria and assessing safety concerns and in vitro versus clinical efficacy.

The lecture reviews the proposition of ivermectin as a COVID-19 treatment, noting its veterinary and topical medical uses, in vitro SARS-CoV-2 inhibition, mixed clinical results, and dose-related toxicity concerns.

Examine the proposed use of oleandrin from oleander as a COVID-19 treatment, noting its toxicity, inconclusive and unpublished in vitro studies, and lack of FDA approval.

Dexamethasone serves as a covid 19 treatment that reduces mortality in severe cases but is not effective in early infection, acting through genomic and immune-suppression mechanisms.

Assess antiviral options for Covid-19, including remdesivir as a repurposed RNA polymerase inhibitor, molnupiravir as a cytodyn derivative inducing viral mutations, and protease-inhibiting approaches to block polyprotein cleavage.

Define monoclonal antibody therapy and contrast it with polyclonal antibodies, highlighting cloning to select affinity against a target. Discuss bamlanivimab and sotrovimab, their FDA-approved non-hospitalized use and variant efficacy.

Explore how bone marrow and thymus generate immune cells, with lymph nodes and spleen organizing responses, while innate and adaptive immunity coordinate through pattern recognition and antigen presentation.

Explore adaptive immunity, detailing antibody and cytotoxic T cell responses to extracellular versus intracellular antigens, and how memory, tolerance, and clonal selection enable rapid secondary responses.

Explore the vaccine development process from preclinical research to phase one and phase two trials, assessing safety, seroconversion, antibody and T-cell responses, and dosing strategies.

Explain phase three and four vaccine development with randomized double-blind trials, diverse populations, and efficacy versus relative risk, plus post-market effectiveness and endpoints such as infection, hospitalization, and death.

Examine traditional vaccine approaches, including inactivated vaccines and subunit vaccines, with examples like Coronavac, Sinovac, Covaxin and Novavax, and note boosters and adjuvants.

Viral vector vaccines use a non-replicating carrier virus to deliver COVID-19 genetic information and produce the spike protein inside cells, triggering antibody and cellular immune responses.

Explore how messenger RNA vaccines use viral genetic information to produce the spike protein, delivered in a lipid layer, triggering an immune response and highlighting advantages and disadvantages.

Explore the influenza virus, its main strains A, B, and C, with influenza A most relevant to humans, its segmented RNA genome, hemagglutinin and neuraminidase proteins, and annual vaccines.

Learn how HIV, a lentivirus retrovirus, uses reverse transcriptase to convert RNA to DNA, integrates into the host genome, and spreads mainly through sexual transmission, with antiretroviral therapy controlling disease.

Explore the SARS-CoV-2 virus and COVID-19 disease, including virus structure and genome, treatments and vaccines, immunology and vaccinology, and epidemiology across genetics, cell biology, pharmacology, and virology.